Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1766 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
LETTER TO THE EDITOR
Year : 2013  |  Volume : 17  |  Issue : 6  |  Page : 1133

Antidyslipidemic drugs in metabolic syndrome


Freelance Consultant, Medical Communication and Training, B-101, Balaji Bhavan CHS, Sector 44 A, Nerul, Navi Mumbai, India

Date of Web Publication3-Dec-2013

Correspondence Address:
Anant D Patil
B 101, Balaji Bhavan CHS, Sector 44 A, Nerul 400 706, Navi Mumbai
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.122652

Rights and Permissions

How to cite this article:
Patil AD. Antidyslipidemic drugs in metabolic syndrome. Indian J Endocr Metab 2013;17:1133

How to cite this URL:
Patil AD. Antidyslipidemic drugs in metabolic syndrome. Indian J Endocr Metab [serial online] 2013 [cited 2019 Nov 18];17:1133. Available from: http://www.ijem.in/text.asp?2013/17/6/1133/122652

Sir,

I read with interest the original article "Dyslipidemic drugs in metabolic syndrome" published by Siddiqui et al. [1]

At the outset, I wish to compliment the authors for conducting first study which evaluated the lipid-lowering effect of rosuvastatin versus a combination of atorvastatin and ezetimibe in metabolic syndrome in the Indian patients. Their study result showed the combination of atorvastatin plus ezetimibe to be more efficacious than rosuvastatin. In terms of safety profile, combination of atorvastatin plus ezetimibe was found to be comparable to rosuvastatin. The results of this study will surely help clinicians to use combination of ezetimibe plus atorvastatin to achieve low-density lipoproteincholesterol (LDL-C) goal and avoid the risk of high-dose statin monotherapy in deserving patients.

I think inadvertently the title of original article has been given as "Dyslipidemic drugs in metabolic syndrome" instead of "Antidyslipidemic drugs in metabolic syndrome."

I feel, changing the title of the original article as "Antidyslipidemic drugs in metabolic syndrome" will help to attract more readers to study results and in turn more physicians will extend the benefit of combination to the patients who deserve this treatment.

 
   References Top

1.Siddiqi SS, Misbahuddin, Ahmad F, Rahman SZ, Khan AU. Dyslipidemic drugs in metabolic syndrome. Indian J Endocrinol Metab 2013;17:472-9.  Back to cited text no. 1
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed602    
    Printed8    
    Emailed0    
    PDF Downloaded147    
    Comments [Add]    

Recommend this journal